Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AstraZeneca vaccine could curb COVID-19 transmission

By Brian Buntz | February 3, 2021

Hopes for COVID-19 vaccines to beat back the pandemic assumed mass-vaccination would slow viral transmission, and not just prevent moderate-to-severe disease.

Now, early data suggest that AstraZeneca’s (LON:AZN) COVID-19 vaccine, which it jointly developed with Oxford University, can curb viral transmission by up to 67%. The researchers didn’t study transmissibility per se; the inferred it by taking weekly PCR swab tests from volunteers. The first dose led to the 67% reduction in PCR positivity while the second dose led to a 50% reduction.

There was more good news from the data. The ChAdOx1 vaccine offered 100% protection against severe disease in a Phase 3 trial. A single vaccine dose offered 76% efficacy between 22 and 90 days after vaccination. Delaying the second dose of vaccine by 12 weeks appeared to boost efficacy to 82%. Efficacy fell to 55% when the gap between doses dropped to less than six weeks.

The study concluded that the U.K.’s strategy of aiming to vaccinate a large proportion of the population with the first dose before administering the second vaccine dose up to 12 weeks later is “an effective strategy.”

Also heartening is the fact that a portion of the data came from regions with highly transmissible variants, including Brazil (Phase 3) and South Africa (Phase 2).

While a single vaccine dose was effective at engendering short-term immunity, vaccine efficacy fell to 32% between 90 and 120 days after administration of a single-dose shot. “A second dose of ChAdOx1 nCoV-19 induces increased neutralising antibody levels and is likely necessary for long lasting protection,” the researchers concluded in the preprint article in The Lancet.

The U.S. has not yet authorized the AstraZeneca vaccine as the FDA is awaiting more results from a Phase 3 clinical trial, which are due later this month.

 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: AstraZeneca plc, clinical trials, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE